Credit Suisse Ag Ocular Therapeutix, Inc Transaction History

Credit Suisse Ag

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$2.61 - $4.41 $1,140 - $1,927	-437 Reduced 99.32%	3 $0
Q3 2022 Nov 10, 2022	BUY	$4.09 - $6.5 $1,799 - $2,860	440 New	440 $2,000
Q2 2022 Aug 12, 2022	SELL	$3.01 - $5.22 $183,739 - $318,644	-61,043 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$4.83 - $7.35 $76,512 - $116,431	15,841 Added 35.04%	61,043 $302,000
Q4 2021 Feb 14, 2022	BUY	$6.16 - $12.07 $35,062 - $68,702	5,692 Added 14.41%	45,202 $316,000
Q3 2021 Nov 12, 2021	BUY	$9.7 - $14.34 $21,660 - $32,021	2,233 Added 5.99%	39,510 $396,000
Q2 2021 Aug 16, 2021	SELL	$13.43 - $19.16 $74,133 - $105,763	-5,520 Reduced 12.9%	37,277 $529,000
Q1 2021 May 14, 2021	SELL	$15.82 - $22.11 $350,539 - $489,913	-22,158 Reduced 34.11%	42,797 $701,000
Q4 2020 Feb 12, 2021	BUY	$7.91 - $22.95 $513,794 - $1.49 Million	64,955 New	64,955 $1.34 Million
Q2 2019 Aug 14, 2019	SELL	$2.46 - $4.52 $35,515 - $65,255	-14,437 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$3.51 - $4.77 $50,673 - $68,864	14,437 New	14,437 $57,000
Q3 2018 Nov 13, 2018	SELL	$5.42 - $6.99 $181,933 - $234,633	-33,567 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$5.99 - $8.17 $11,045 - $15,065	-1,844 Reduced 5.21%	33,567 $226,000
Q1 2018 May 15, 2018	SELL	$4.66 - $7.08 $4,142 - $6,294	-889 Reduced 2.45%	35,411 $230,000
Q4 2017 Feb 14, 2018	SELL	$3.73 - $6.37 $778,988 - $1.33 Million	-208,844 Reduced 85.19%	36,300 $161,000
Q3 2017 Nov 14, 2017	BUY	$5.28 - $6.88 $1.21 Million - $1.58 Million	229,349 Added 1452.04%	245,144 $1.52 Million
Q2 2017 Aug 14, 2017	BUY	N/A	15,795	15,795 $146,000

151

136M

86.4K

263K

Ticker OCUL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,966,896
Market Cap $668M
Description
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cat...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.